Spectrum Medical
UK maker of cardiac perfusion machines and monitoring software for heart surgery.
On the record
Checkpoint: FDA re-inspection outcome on the 2024 warning letter and VIPER clearance status
The call
A profitable perfusion business with real installed base now carries three FDA actions in 18 months while Medtronic and LivaNova ship rival platforms into the same hospitals.
Spectrum Medical makes equipment and software that doctors use during heart surgery to manage blood flow and keep patients stable. The company has real customers locked in by contracts and regulatory approvals, but it is not hard to replace because giant medical companies like Medtronic, LivaNova, and Terumo are already selling competing systems to the same hospitals, and these giants have way more money and reach. The one thing that could change everything is whether the U.S. Food and Drug Administration takes stronger action: the company received a warning letter in 2023, recalled a pump part in October 2024, and recalled software in March 2025, which is three strikes in 18 months and suggests a pattern of compliance problems that could lead to forced shutdowns, import bans, or major redesigns that would cripple the business.
Why
01
AI pressure: None apparent. No AI product targets perfusion monitoring yet; the software is tied to Spectrum's own hardware and hospital workflows. Could AI do the core job? Unlikely.
02
Bigger players: Medtronic (VitalFlow) and LivaNova (Essenz). Medtronic, LivaNova, Terumo and Getinge already sell competing perfusion and ECMO platforms, and together with Fresenius hold over 70% of the market. Could a giant copy it? Yes, easily.
03
What protects it. FDA/CE clearances, hospital service contracts, and switching costs from swapping out installed perfusion consoles protect its base.
What would change this call
FDA issues a fourth enforcement action, import alert, or consent decree tied to Spectrum's 2023 warning letter or recalls. Would show the regulatory problem is worsening rather than being resolved.
CVC hires bankers, files an S-1, or starts a sale process for Spectrum Medical. Would show CVC is moving toward an exit on its own timeline.
Hospital systems publicly switch from Spectrum's Quantum Perfusion platform to Medtronic VitalFlow or LivaNova Essenz. Would confirm rivals are actively capturing Spectrum's installed base.
CVC hires bankers, files an S-1, or starts a sale process for Spectrum Medical. Would show CVC is moving toward an exit on its own timeline.
Hospital systems publicly switch from Spectrum's Quantum Perfusion platform to Medtronic VitalFlow or LivaNova Essenz. Would confirm rivals are actively capturing Spectrum's installed base.
Key numbers
- 2023 revenue £82.9M
- CVC valued company at up to £1 billion
- 156 VIPER systems recalled across ~40 US states
Named risks
- Three FDA compliance actions in 18 months: 2023 warning letter, October 2024 and March 2025 recalls.
- Operates in consolidated market where top five giants hold 70%+ share and ship competing platforms.
- PE ownership since July 2022 creates exit-timing uncertainty outside company's control.
- Recent headcount and 2024-2025 revenue figures are unverified or conflicting across sources.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Medtronic | gaining on | Launched VitalFlow ECMO platform, one of top five incumbents holding 70%+ market share as of 2024 |
| LivaNova | gaining on | Launched Essenz modular CPB system in Europe, February 2023 |
| Terumo | contesting | CDI 500 is direct rival to Spectrum's M4 monitoring line; Terumo called world's leading perfusion supplier |
| Getinge | gaining on | Named among top five incumbents controlling over 70% of perfusion/ECMO market, 2024 |
Questions people ask
- Is Spectrum Medical profitable?
- Spectrum Medical reported £82.9 million in sales for 2023, a figure attributed to the company by The Times in a January 2025 profile. No public loss disclosure exists, and the business has operated as a going concern with a real installed base since its 2006 founding under CEO Steve Turner.
- Who owns Spectrum Medical?
- CVC Fund VIII signed a definitive agreement in July 2022 to invest in Spectrum Medical Group, valuing the company at up to £1 billion. Founders Steve Turner (CEO) and Mark Drain (CFO) remained on the leadership team after the private equity deal closed.
- Has Spectrum Medical had FDA compliance problems?
- Yes. Spectrum Medical received an FDA warning letter (posted April 2024) over off-label marketing of Quantum Perfusion devices, followed by a Class 2 recall of roller-pump components in October 2024 and a Class 2 recall of its VIPER software in March 2025 for lacking FDA clearance.
- Who are Spectrum Medical's biggest competitors?
- Spectrum Medical competes against Medtronic (VitalFlow ECMO platform), LivaNova (Essenz modular CPB system, launched February 2023), Terumo (CDI 500, a direct rival to Spectrum's M4 monitor), and Getinge. Market research from 2024 shows the top five perfusion/ECMO incumbents hold over 70% share.
- Could AI replace Spectrum Medical's products?
- Unlikely for its core hardware. Spectrum's cardiac perfusion pumps and oxygenators are physical, FDA/CE-regulated, life-critical devices untouched by frontier AI. Its smaller Quantum Informatics software layer, including the VIPER monitoring tool recalled in March 2025, is the only part with meaningful AI exposure.
- What is Spectrum Medical worth?
- CVC Fund VIII's July 2022 investment valued Spectrum Medical Group at up to £1 billion, the basis for its unicorn status. This valuation stems from a private equity deal, not a public market price, and no newer valuation has been publicly disclosed since.
Timeline
- 2025-04-28FDA Class 2 recall of Quantum Informatics VIPER software, 156 systems in ~40 US states, marketed without clearance
- 2024-10-23FDA Class 2 recall of Quantum Perfusion Systems roller pump components
- 2024-04-01FDA posts warning letter alleging off-label marketing of Quantum Perfusion devices
- 2023-09-29FDA inspection of Spectrum Medical Ltd leads to later warning letter
- 2023-02-01LivaNova launches competing Essenz modular CPB system in Europe
- 2022-07-18CVC Fund VIII signs deal to invest in Spectrum Medical, valuing it at up to £1 billion
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- CVC Fund VIII invests in Spectrum Medical Group (2022-07-18)
- Spectrum Medical (2025-01-13)
- Spectrum Medical Stock Price, Funding, Valuation, Revenue & Financial Statements (2026-02-22)
- Spectrum Medical (2026-03-05)
- Class 2 Device Recall Quantum Informatics VIPER (2025-04-28)
- Spectrum Medical Ltd - 666543 - 09/29/2023
- Medical Device Recalls (2024-10-23)
- ECMO Machines Companies, Top ECMO Machines Manufacturers
- Accuracy of the Spectrum Medical M4 and Terumo CDI 500... (2017-09-30)
- Perfusion Systems Global Market Report 2023 (2023-08-24)
- Products, Competitors, Financials, Employees, Headquarters Locations (2026-02-22)